Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News report.faq_name
On This Report

Smart Insulin Pens & Pumps Market Size & Growth Forecast 2026–2035, By Segments (Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 12606| Published Date: Apr-2026| Format: PDF, Excel
MARKET OUTLOOK

Market Size and Growoth Outlook

Smart Insulin Pens & Pumps Market size was more than USD 7.94 Billion in 2025 and is set to grow at a 8.4% CAGR between 2026 and 2035, exceeding USD 17.79 Billion by 2035. The industry revenue for 2026 is assessed at USD 8.52 billion.

Base Year Value (2025)
USD 7.94 Billion
CAGR (2026-2035)
8.4%
Forecast Year Value (2035)
USD 17.79 Billion
Historical Data Period
2022-2025
Largest Region
Europe
Forecast Period
2026-2035

Get more details on this report

Request Free Sample Report
SNAPSHOT

Smart Insulin Pens & Pumps Market Intelligence Snapshot

Regional Market Dynamics

  • Europe captured 33.81% of the market in 2025, supported by established diabetes care infrastructure, broad technology access, mature reimbursement systems, and widespread clinical adoption of connected insulin management.
  • Asia Pacific is projected to grow at a 9.49% CAGR, driven by rising diabetes incidence, expanding digital health adoption, greater healthcare investment, and increasing availability of advanced insulin delivery devices.

Segment Momentum

  • Smart insulin pumps accounted for 61.53% of the market in 2025, supported by their role in continuous insulin delivery, treatment precision, automated dosing support, and integration into comprehensive diabetes management routines.
  • Homecare is growing fastest as patients increasingly manage diabetes independently using connected devices. Convenience, continuous monitoring, and improved support for day-to-day insulin management are accelerating adoption outside clinical settings.

Market Expansion Drivers

  • Rising global diabetes prevalence increasing demand for precise insulin delivery devices.
  • Growing adoption of digital health tools enabling connected glucose monitoring and insulin management.
  • Advancements in wearable drug delivery systems improving dosing accuracy and patient adherence.

Leading Market Participants

FORECAST SNAPSHOT

Global Market Forecast Snapshot

Market Outlook

Key companies in the smart insulin pens & pumps market include Novo Nordisk A/S (Denmark), Sanofi S.A. (France), Medtronic plc (Ireland), Insulet Corporation (United States), Tandem Diabetes Care, Inc. (United States), Abbott Laboratories (United States), F. Hoffmann-La Roche AG (Switzerland), Ypsomed AG (Switzerland), SOOIL Development Co., Ltd. (South Korea), Emperra GmbH E-Health Technologies (Germany).

Regional and Segment Outlook

Europe
MARKET DYNAMICS

Market Growth Drivers and Industry Trends

Rising global diabetes prevalence increasing demand for precise insulin delivery devices

As the number of people requiring daily insulin therapy rises, treatment decisions are shifting toward devices that can reduce dosing errors, simplify administration, and support tighter glycemic control. In the smart insulin pens & pumps market, this expands demand beyond basic delivery hardware toward connected systems that help patients and clinicians manage frequent dose adjustments, missed injections, and variable insulin needs. The practical effect is stronger purchasing interest from healthcare providers, diabetes clinics, and self-managing patients seeking more reliable insulin delivery, particularly where long-term disease management is becoming a larger burden on care systems.

Growing adoption of digital health tools enabling connected glucose monitoring and insulin management

The spread of app-based diabetes management, continuous glucose monitoring platforms, and remote care models is influencing market adoption by making connected insulin devices more useful in everyday treatment. In the smart insulin pens & pumps market, devices that can sync dosing data with glucose readings give patients a clearer view of insulin response and allow clinicians to review therapy patterns without relying on manual logs. That integration is shaping buying decisions in favor of pens and pumps that fit into broader digital care workflows, aiding market expansion through better data visibility, more personalized insulin titration, and easier ongoing monitoring.

Advancements in wearable drug delivery systems improving dosing accuracy and patient adherence

Progress in miniaturized sensors, automated delivery controls, and more comfortable wearable formats is driving market development by making insulin therapy less intrusive and more consistent. In the smart insulin pens & pumps market, improved device design reduces the friction associated with multiple daily dosing decisions, while more accurate delivery mechanisms help limit underdosing, overdosing, and missed administration. This is increasing market adoption among patients who need sustained insulin support but are sensitive to convenience, discretion, and ease of use, especially as treatment outcomes become more closely tied to adherence over long management periods.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Rising global diabetes prevalence increasing demand for precise insulin delivery devices 2.10% High North America, Asia Pacific High Near Term
Growing adoption of digital health tools enabling connected glucose monitoring and insulin management 1.80% High North America, Europe High Near Term
Advancements in wearable drug delivery systems improving dosing accuracy and patient adherence 1.50% Moderate Europe, Asia Pacific Medium Mid Term
CUSTOM RESEARCH

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
REGIONAL FORECAST

Regional Demand Dynamics

Polymer Modified Bitumen Market
Largest Region
Europe
33.81% Market Share in 2025
Europe (Largest Region) vs Asia Pacific (Fastest-Growing Region)

Europe held a 33.81% share of the smart insulin pens & pumps market in 2025, supported by its established diabetes care infrastructure, broad access to advanced insulin delivery technologies, and strong clinical familiarity with connected management tools. The region’s leadership is reinforced by the routine integration of device-based glucose and insulin management into outpatient care, which helps sustain demand for smart pens and pumps among both providers and patients. Adoption is further supported by a mature reimbursement environment and a large treated diabetic population, allowing manufacturers to commercialize and scale advanced delivery systems more effectively across the region.

Asia Pacific is projected to expand at a 9.49% CAGR over the forecast period in the smart insulin pens & pumps market, driven primarily by rising diabetes incidence, improving access to modern diabetes treatment, and broader uptake of digital health technologies in clinical practice. Growth is accelerating as healthcare systems across the region invest more actively in diabetes monitoring and treatment pathways, creating practical openings for connected insulin delivery devices beyond major urban centers. Expanding patient awareness, alongside increasing availability of advanced therapeutic devices, is also helping shift treatment adoption from conventional insulin administration toward smarter, more data-enabled formats.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
COUNTRY INSIGHTS

Key Country Insights

Germany 🇩🇪

Precision Therapy Adoption

Germany is emphasizing technologically advanced insulin delivery devices that improve treatment adherence and glycemic control. The market in Germany is benefiting from strong interest in connected diabetes management solutions integrated with digital healthcare ecosystems.

France 🇫🇷

Patient Adherence Solutions

France is focusing on smart insulin technologies that improve treatment compliance and facilitate better diabetes monitoring. The market in France is seeing increased interest in devices that integrate dosing information with digital platforms to support patient engagement and clinical oversight.

Italy 🇮🇹

Home-Based Diabetes Care

Italy is encouraging the use of smart insulin pens and pumps to support diabetes management outside traditional clinical settings. Healthcare providers in Italy are increasingly adopting connected devices that improve convenience and help optimize insulin administration for chronic care patients.

Japan 🇯🇵

Elderly Care Support

Japan is adopting smart insulin pens and pumps that simplify diabetes management for an aging population with increasing chronic disease prevalence. Healthcare providers in Japan are prioritizing user-friendly devices that enhance dosing accuracy and support long-term disease management.

South Korea 🇰🇷

Digital Health Integration

South Korea is leveraging its advanced digital healthcare infrastructure to support adoption of connected insulin delivery technologies. Patients and clinicians in South Korea are increasingly using smart insulin devices that enable real-time monitoring and data-driven treatment adjustments.

United States 🇺🇸

Connected Diabetes Management

The U.S. smart insulin pens and pumps market is rapidly incorporating continuous glucose monitoring integration and digital health platforms. Healthcare providers in the U.S. are increasingly recommending connected insulin delivery systems that support personalized therapy and remote patient management.

SEGMENT ANALYSIS

Segment Leadership and Growth Trends

Smart Insulin Pens & Pumps Market Share (%), Type, 2025

Smart Insulin Pumps
Smart Insulin Pens

Go beyond the chart, access full insights & data tables

Request Free Sample Report
Type Segment Analysis: Smart Insulin Pumps (Largest Segment) vs Smart Insulin Pens (Fastest-Growing Segment)

Smart Insulin Pumps held the dominant position in the smart insulin pens & pumps market in 2025, accounting for a 61.53% share. Their leadership is maintained through their established role in continuous insulin delivery for patients who require tighter glucose management and more automated dosing support. In practical care settings, smart insulin pumps are often preferred where treatment precision, dosing consistency, and integration with broader diabetes management routines are critical, which helps preserve their dominant share in the market.

Smart Insulin Pens are emerging as the fastest-growing segment in the smart insulin pens & pumps market because they address a more accessible and less complex route to connected insulin management. Their momentum is supported by growing demand for user-friendly devices that improve dose tracking and adherence without the higher operational burden associated with pump therapy. Relative to pumps, smart insulin pens fit more easily into routine outpatient and self-managed care, which is strengthening their growth trajectory across a broader patient base.

End Use Segment Analysis: Hospitals and Clinics (Largest Segment) vs Homecare (Fastest-Growing Segment)

Within the smart insulin pens & pumps market, Hospitals and Clinics represented the largest end-use segment in 2025 with a 51.2% share. This leadership reflects the central role of clinical environments in initiating insulin therapy, managing complex diabetes cases, and supervising device adoption for patients who need structured monitoring and professional support. The segment’s share remains strong because hospitals and clinics serve as key points for diagnosis, treatment adjustment, and technology-based diabetes care delivery.

Homecare is the fastest-growing end-use segment in the smart insulin pens & pumps market, driven by the broader shift toward self-management of chronic conditions outside institutional settings. Growth is gaining pace as connected insulin devices become better aligned with day-to-day patient use, allowing individuals to manage dosing, monitoring, and adherence more independently. Compared with facility-based care, homecare benefits from the practical need for convenience and continuity in long-term diabetes management, which is accelerating adoption in this segment.

Segment Sub-Segment Largest Segment Fastest Growing
Type Smart Insulin Pens, Smart Insulin Pumps Smart Insulin Pumps Smart Insulin Pens
End Use Hospitals and Clinics, Homecare, Others Hospitals and Clinics Homecare
Competitive Landscape

Competitive Landscape and Market Positioning

Key companies in the smart insulin pens & pumps market:

1. Novo Nordisk A/S (Denmark)

2. Sanofi S.A. (France)

3. Medtronic plc (Ireland)

4. Insulet Corporation (United States)

5. Tandem Diabetes Care Inc. (United States)

6. Abbott Laboratories (United States)

7. F. Hoffmann-La Roche AG (Switzerland)

8. Ypsomed AG (Switzerland)

9. SOOIL Development Co. Ltd. (South Korea)

10. Emperra GmbH E-Health Technologies (Germany)

The smart insulin pens & pumps market is advancing through integration of connected health technologies that enable real-time glucose management. Within the smart insulin pens & pumps market, digital ecosystems are expanding to support personalized diabetes care and monitoring. Research efforts are enhancing dosing accuracy and improving user-centric device intelligence. Increasing adoption of smart healthcare systems is strengthening treatment adherence and patient outcomes.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Novo Nordisk Jun-24 Novo Nordisk announced an investment of approximately USD 4.1 billion to construct a manufacturing facility in North Carolina to expand production capacity for injectable treatments targeting obesity and chronic diseases. The investment strengthens its manufacturing footprint and supports long-term supply scalability across its diabetes and metabolic care portfolio.
Abbott Sep-23 Abbott acquired Bigfoot Biomedical, a developer of smart insulin management systems, to expand its diabetes care ecosystem. The acquisition strengthens Abbott’s connected diabetes portfolio by integrating smart insulin technologies and supporting the development of personalized, data-driven insulin management solutions.
Novo Nordisk Jun-23 Novo Nordisk announced its intention to acquire Biocorp, a medical device company specializing in connected drug delivery technologies. The acquisition is aimed at integrating Biocorp’s expertise into the development of next-generation connected insulin pens, strengthening Novo Nordisk’s position in smart insulin delivery solutions.
Novo Nordisk Oct-22 Novo Nordisk launched smart insulin pens including NovoPen 6 and NovoPen Echo Plus in Ireland to enhance digital insulin dosing and tracking capabilities. The launch supports broader adoption of connected diabetes management tools and strengthens its smart insulin delivery product portfolio in European markets.
Novo Nordisk Sep-22 Novo Nordisk received regulatory approval from China’s NMPA for NovoPen 6, a smart insulin pen capable of automatically recording insulin dose and timing. The approval supports market expansion in China and reinforces the company’s regulatory progress in connected diabetes management devices.
Novo Nordisk Mar-22 Novo Nordisk expanded access to its smart insulin pens NovoPen 6 and NovoPen Echo Plus through availability to NHS patients in the United Kingdom. The rollout supports improved insulin dose tracking and strengthens integration of digital diabetes management tools within public healthcare systems.
Medtronic Aug-20 Medtronic acquired Companion Medical, the manufacturer of the InPen smart insulin pen system, to expand its diabetes management portfolio. The acquisition strengthens Medtronic’s connected insulin delivery ecosystem and supports broader adoption of smart insulin dosing technologies for diabetes care.
Report Customization

Explore This Report

Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.

1 report.custom report.segments 2 Custom TOC 3 Related Reports

Smart Insulin Pens & Pumps Market — Custom Segments

Segment Sub-Segment
No segment data available.

Smart Insulin Pens & Pumps Market — report.custom

Custom Chapter Custom Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
report.faq_name

What is the current size of the smart insulin pens & pumps market?

The market size of smart insulin pens & pumps in 2026 is calculated to be USD 8.52 billion.

How much is the smart insulin pens & pumps industry expected to grow by 2035?

Smart Insulin Pens & Pumps Market size is projected to expand significantly moving from USD 7.94 billion in 2025 to USD 17.79 billion by 2035 with a CAGR of 8.4% during the 2026-2035 forecast period.

How is digital health integration changing demand for smart insulin delivery systems?

Connected glucose monitoring and remote care workflows are encouraging adoption of insulin devices that provide dosing visibility, enable personalized management, and improve coordination between patients and clinicians.

Which device advancements are strengthening adoption of smart insulin pens and pumps?

Improvements in wearable formats, automated controls, and delivery accuracy are increasing preference for systems that improve convenience, adherence, and consistency in long-term insulin management.

Why do smart insulin pumps lead the smart insulin pens & pumps market?

Smart insulin pumps accounted for 61.53% of the market in 2025, supported by their role in continuous insulin delivery, treatment precision, automated dosing support, and integration into comprehensive diabetes management routines.

Why is homecare the fastest-growing end-use segment in the smart insulin pens & pumps market?

Homecare is growing fastest as patients increasingly manage diabetes independently using connected devices. Convenience, continuous monitoring, and improved support for day-to-day insulin management are accelerating adoption outside clinical settings.

Why does Europe hold the largest share of the smart insulin pens and pumps market?

Europe captured 33.81% of the market in 2025, supported by established diabetes care infrastructure, broad technology access, mature reimbursement systems, and widespread clinical adoption of connected insulin management.

What factors are accelerating market growth in Asia Pacific?

Asia Pacific is projected to grow at a 9.49% CAGR, driven by rising diabetes incidence, expanding digital health adoption, greater healthcare investment, and increasing availability of advanced insulin delivery devices.

Who are the leading players in the smart insulin pens & pumps landscape?

Key companies in the smart insulin pens & pumps market include Novo Nordisk A/S (Denmark), Sanofi S.A. (France), Medtronic plc (Ireland), Insulet Corporation (United States), Tandem Diabetes Care, Inc. (United States), Abbott Laboratories (United States), F. Hoffmann-La Roche AG (Switzerland), Ypsomed AG (Switzerland), SOOIL Development Co., Ltd. (South Korea), Emperra GmbH E-Health Technologies (Germany).
Testimonials

Our Clients

"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."

Quality Assurance Manager

"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."

R&D Manager

"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."

Senior Marketing Manager
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →